Last reviewed · How we verify
RUTI®
At a glance
| Generic name | RUTI® |
|---|---|
| Also known as | FCMtb is the active compound of the vaccine RUTI |
| Sponsor | Archivel Farma S.L. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Efficacy of Lactobacillus Crispatus M247 in the Prevention and Treatment of Recurrent Urinary Tract Infections (NA)
- Vitamin C and Hiprex in rUTI (EARLY_PHASE1)
- Safety and Efficacy of RUTI® With the Standard of Treatment for Tuberculosis (PHASE2)
- Clinical Trial to Investigate Therapeutic Vaccine (RUTI) Against Tuberculosis (TB) (PHASE2)
- Alternative Prophylaxis in Female Recurrent Urinary Tract Infections (PHASE4)
- Immunological Response to Intravesical BCG Therapy of Superficial Bladder Cancer by Prior Administration of RUTI® (PHASE1)
- A Clinical Trial to Evaluate the Efficacy of RUTI® to Reduce the Severity of SARS-CoV-2 Infection (COVID-19) (PHASE2,PHASE3)
- Exploratory Study to Evaluate the Efficacy of RUTI® Against SARS-COV-2 Infection (COVID-19) in Healthcare Workers (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RUTI® CI brief — competitive landscape report
- RUTI® updates RSS · CI watch RSS
- Archivel Farma S.L. portfolio CI